Neovacs SA (France) Probability of Future Stock Price Finishing Under 0.0011
| ALNEV Stock | EUR 2.00 0.78 28.06% |
Neovacs |
Neovacs SA Target Price Odds to finish below 0.0011
The tendency of Neovacs Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to € 0 or more in 90 days |
| 2.00 | 90 days | 0 | roughly 2.15 |
Based on a normal probability distribution, the odds of Neovacs SA to drop to € 0 or more in 90 days from now is roughly 2.15 (This Neovacs SA probability density function shows the probability of Neovacs Stock to fall within a particular range of prices over 90 days) . Probability of Neovacs SA price to stay between € 0 and its current price of €2.0 at the end of the 90-day period is about 16.78 .
Assuming the 90 days trading horizon the stock has the beta coefficient of 2.52 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Neovacs SA will likely underperform. Additionally Neovacs SA has an alpha of 0.2817, implying that it can generate a 0.28 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Neovacs SA Price Density |
| Price |
Predictive Modules for Neovacs SA
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neovacs SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neovacs SA's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neovacs SA Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neovacs SA is not an exception. The market had few large corrections towards the Neovacs SA's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neovacs SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neovacs SA within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 2.52 | |
σ | Overall volatility | 1.75 | |
Ir | Information ratio | 0.02 |
Neovacs SA Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neovacs SA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neovacs SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neovacs SA is way too risky over 90 days horizon | |
| Neovacs SA appears to be risky and price may revert if volatility continues | |
| Neovacs SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.59 K. Net Loss for the year was (11.84 M) with loss before overhead, payroll, taxes, and interest of (4.54 M). | |
| Neovacs SA has accumulated about 1.42 M in cash with (9.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Neovacs SA Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neovacs Stock often depends not only on the future outlook of the current and potential Neovacs SA's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neovacs SA's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1509.64 | |
| Cash And Short Term Investments | 33.1 M |
Neovacs SA Technical Analysis
Neovacs SA's future price can be derived by breaking down and analyzing its technical indicators over time. Neovacs Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Neovacs SA. In general, you should focus on analyzing Neovacs Stock price patterns and their correlations with different microeconomic environments and drivers.
Neovacs SA Predictive Forecast Models
Neovacs SA's time-series forecasting models is one of many Neovacs SA's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Neovacs SA's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Neovacs SA
Checking the ongoing alerts about Neovacs SA for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Neovacs SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Neovacs SA is way too risky over 90 days horizon | |
| Neovacs SA appears to be risky and price may revert if volatility continues | |
| Neovacs SA has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.59 K. Net Loss for the year was (11.84 M) with loss before overhead, payroll, taxes, and interest of (4.54 M). | |
| Neovacs SA has accumulated about 1.42 M in cash with (9.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.